Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis

Current Rheumatology Reviews

Volumn 6, Issue 4, 2010, Pages 283-294

  Jiménez, Sergio A ^a   Castro, Susan V ^a   Piera Velázquez, Sonsoles ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CAVEOLIN 1; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C DELTA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; DISEASE ASSOCIATION; FIBROSIS; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

EID: 78649346798     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339710793205611     Document Type: Article

References (150)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Int Med 2004; 140: 37-50.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
3. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 134-44.
4. Gabrieli A, Avvediemento EV, Krieg T. Mechanisms of disease: Scleroderma. N Engl J Med 2009; 360; 1989-2003.
5. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 1996; 22: 647-74.
6. Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002; 7: c608-18.
7. Kissin EY, Korn JH. Fibrosis in scleroderma. Rheum Dis Clin North Am 2003; 29: 351-69.
8. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008; 34: 115-43.
9. LeRoy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972; 135: 1351-2.
10. Strehlow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10: 572-8.
11. Eyden B. The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med 2008; 12: 22-37.
12. Kalluri R, Nielson EG. Epithelial-mesenchymal transitions and it implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
14. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
15. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004; 16: 733-8.
16. Botstein GR, Sherer GK, LeRoy EC. Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum 1982; 25:189-95.
17. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
18. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
19. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2005; 36: 598-606.
20. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 145-50.
21. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007; 9: 136-43.
22. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-tomesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
23. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-tomesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-7.
24. Hashimoto N, Phan SH, Imaizumi K, et al. Endothelialmesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43(2): 161-72.
25. Roberts AB, Sporn MB. Transforming growth factor beta. Adv Cancer Res 1988; 51: 107-45.
26. Roberts AB, Flanders KC, Kondaiah P, et al. Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog Horm Res 1988; 44: 157-97.
27. Massague J, Cheifetz S, Ignotz RA, Boyd FT. Multiple type-beta transforming growth factors and their receptors. J Cell Physiol 1987; 5: s43-7.
28. Miyazono K, Olofsson, A, Colosetti P, Heldin CH. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta1. EMBO J 1991; 10: 1091-101.
29. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994; 124: 171-81.
30. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69.
31. Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 2005; 24: 395-402.
32. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-78.
33. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296: 1646-7.
34. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGFβ family signalling. Nature 2003; 425: 577-84.
35. Ten Dijke P, Hill CS. New insights into TGF-β-Smad signaling. Trends Biochem 2004; 29: 265-74.
36. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthrits Rheum 2002; 46: 1703-1713.
37. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40: 383-408.
38. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007; 282: 10405-13.
39. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-44.
40. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signaling. Nature 1997; 389: 631-5.
41. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89: 1165-73.
42. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 2000; 6: 1365-1375.
43. Moustakas A, Heldin C-H. Non-Smad TGF-β signals. J Cell Sci 2005; 118: 3573-84.
44. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-39.
45. Bhattacharya S, Ishida W, Wu M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009; 28(10): 1285-97.
46. Pendergast AM, Witte ON. Role of the ABL oncogene tyrosine kinase activity in human leukaemia. Baillieres Clin Haematol 1987; 1: 1001-20.
47. Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia - how does it work? Acta Haematol 2008; 119: 212-7.
48. Rosenbloom J, Jimenez SA. Molecular ablation of TGF-β signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 2008; 58: 2219-24.
49. Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008; 58: 2528-37.
50. Castelino FV, Bhattacharyya S, Varga J. Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib. Curr Rheum Rep 2009; 11(3): 161-3.
51. Rosenbloom J, Castro SV, Jimenez SA. Fibrotic diseases: cellular and molecular mechanisms and novel therapies. (Physiology in Medicine Series). Ann Int Med 2010; 152: 159-67.
52. Bibi Y, Gottlieb AB. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J Am Acad Dermatol 2008; 59: 654-8.
53. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60: 584-91.
54. Downes CP, Carter AN. Phosphoinositide 3-kinase: a new effector in signal transduction? Cell Signal 1991; 3: 501-13.
55. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008; 27: 6473-88.
56. Bujor AM, Pannu J, Bu S, Smith EA, Muise-Helmericks RC, Trojanowska M. Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts. J Invest Dermatol 2008; 128: 1906-14.
57. Jun JB, Kuechle M, Min J, et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 2005; 124: 298-303.
58. Chiang TM, Postlethwaite AE. Alteration in protein kinase B (AKT) activity in platelets form patients with systemic sclerosis. Thromb Res 2008; 122: 501-6.
59. Jimenez SA, Gaidarova S, Saitta B, et al. Role of protein kinase Cdelta in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001; 108: 1395-403.
60. Jinnin M, Ihn H, Yamane K, Mimuar Y, Asano Y, Tamaki K. Alpha1(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 2005; 33: 1337-51.
61. Asano Y, Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol 2009; 29: 1882-94.
62. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003; 5: 410-21.
63. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol 2002; 158: 1239-49.
64. Runyan CE, Schnaper HW, Poncelet AC. The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem 2005; 280: 8300-8.
65. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20: 713-9.
66. Del Galdo F, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854-65.
67. Tourkina E, Richard M, Gööz P, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008; 294(5): L843-61.
68. Le Saux O, Teeters K, Miyasato S, et al. The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties. Am J Physiol Lung Cell Mol Physiol 2008; 295: L1007-17.
69. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
70. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
71. Goumans MJ, Liu Z, ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009; 19: 116-27.
72. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
73. Smith EA, LeRoy EC. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990; 95: 125S-7S.
74. Peltonen J, Kähäri L, Jaakkola S, et al. Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990; 94: 365-71.
75. Gruschwitz M, Müller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94: 197-203.
76. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14: 681-5.
77. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
78. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167-71
79. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261: 4337-45.
80. Varga J, Jimenez SA. Stimulation of normal human fibroblast collagen production and processing by transforming growth factorbeta. Biochem Biophys Res Commun 1986; 138: 974-80.
81. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247: 597-604.
82. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987; 791: 285-8.
83. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann N Y Acad Sci 1990; 580: 225-32.
84. McAnulty RJ, Campa JS, Cambrey AD, Laurent GJ. The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro. Biochim Biophys Acta 1991; 1091: 231-5.
85. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-904.
86. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263: 7741-6.
87. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 2006; 54: 3011-21.
88. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L525-34.
89. Potts JD, Runyan RB. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev Biol 1989; 134: 392-401.
90. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44: 1518-24.
91. Ota H, Kumagai S, Morinobu A, Yanagida H, Nakao K. Enhanced production of transforming growth factor-beta (TGF-β) during autologous mixed lymphocyte reaction of systemic sclerosis patients. Clin Exp Immunol 1995; 100: 99-103.
92. Hasegawa M, Sato S, Takehara K. Augmented production of TGF-β by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004; 296: 89-93.
93. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001; 44: 474-80.
94. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-905.
95. Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 2002; 29: 2558-64.
96. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004; 50: 4008-21.
97. Chen Y, Shi-wen X, Eastwood M, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006; 54: 1309-16.
98. Verrecchia F, Mauviel A, Farge D. Transforming growth factorbeta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 2006; 5: 563-9.
99. Dong C, Zhu S, Wang T, et al. Deficient Smad 7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-13.
100. Mori, Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964-78.
101. Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 2006; 45: 157-65.
102. Sato M, Shegogue D, Gore EA, Smith EA, McDermott PJ, Trojanowska M. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol 2002; 118: 704-11.
103. Bhattacharyya S, Ghosh AK, Pannu J, et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005; 52: 1248-58.
104. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbetaresponsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010; 130: 694-705.
105. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171-9.
106. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003; 81: 355-63.
107. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-10.
108. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19: 113-44.
109. Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004; 122: 1-6.
110. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13: 505-11.
111. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
112. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
113. Bogatkevich GS, Ludwicka-Bradley A, Singleton CB, Bethard JR, Silver RM. Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2008; 295: L603-11.
114. Ross R, Bowen-Pope DF, Raines EW. Platelet-derived growth factor and its role in health and disease. Philos Trans R Soc Lond B Biol Sci 1990; 327: 155-69.
115. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999; 16: 201-16.
116. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
117. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001; 80: 1-38.
118. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-73.
119. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008; 47 (Suppl 5): v2-4.
120. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-34.
121. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 22: 1876-83.
122. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-4.
123. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010; 661: 435-46.
124. Chhina MK, Nargues W, Grant GM, Nathan SD. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol 2010; 6: 19-35.
125. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
126. Gabrielli A, Svegliati S, Moroncini G, Avvedimento EV. Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 2007; 19: 640-5.
127. Classen JF, Henrohn D, Rorsman F, et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009; 60: 1137-44.
128. Loizos N, Lariccia L, Weiner J, et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009; 60: 1145-51.
129. Balada E, Simeón-Aznar CP, Ordi-Ros J, et al. Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 2008; 67: 1027-9.
130. Gospodarowicz D, Neufeld G, Schweigerer L. Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl 1987; (Suppl 5): 15-26.
131. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1989; 1: 207-35.
132. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growht factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
133. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-97.
134. Lawrence A, Khanna D, Misra R, Aggarwal A. Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis. Dermatol Online J 2006; 12: 2.
135. Ichiki Y, Smith EA, LeRoy EC, Trojanowska M. Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen α 2(I) gene expression in scleroderma and normal fibroblasts. J Rheumatol 1997; 24: 90-5.
136. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
137. Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Rheum 2009; 11: 220.
138. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003; 30: 1529-33.
139. Kikuchi K, Kubo M, Kadono T, Yazawa N, IHN H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139: 1049-51.
140. Solanilla A, Villeneuve J, Auguste P, et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 2009; 48: 1036-44.
141. Papaioannou AI, Zakynthinos E, Kostikas K, et al. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 2009; 9: 180.
142. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109-16.
143. Cohick WS, Clemmons DR. The insulin-like growth factors. Ann Ref Physiol 1993; 55: 131-53.
144. Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulinlike growth factors. Annu Rev Physiol 1985; 47: 443-67.
145. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1989; 1: 49-68.
146. Harrison NK, Cambrey AD, Myers AR, et al. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Lond) 1994; 86: 141-8.
147. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick Ca. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166: 399-407.
148. Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008; 35: 2363-71.
149. Hsu E, Feghali-Bostwick CA. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase-and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol 2008; 172: 1580-90.
150. Distler J, Distler O. Novel treatment approaches to fibrosis in scleroderma. Rheum Dis Clin North Am 2008; 34: 145-59; vii.